What's new

Human medicines European public assessment report (EPAR): SomaKit TOC, edotreotide, Date of authorisation: 08/12/2016, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 4, 2025 0

Human medicines European public assessment report (EPAR): SomaKit TOC, edotreoti...

Human medicines European public assessment report (EPAR): Stoboclo, denosumab, Date of authorisation: 14/02/2025, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 4, 2025 0

Human medicines European public assessment report (EPAR): Stoboclo, denosumab, D...

Human medicines European public assessment report (EPAR): Rivastigmine Sandoz, rivastigmine, Date of authorisation: 10/12/2009, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 4, 2025 0

Human medicines European public assessment report (EPAR): Rivastigmine Sandoz, r...

Human medicines European public assessment report (EPAR): Avtozma, tocilizumab, Date of authorisation: 14/02/2025, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 4, 2025 0

Human medicines European public assessment report (EPAR): Avtozma, tocilizumab, ...

Human medicines European public assessment report (EPAR): Rivastigmine Hexal, rivastigmine, Date of authorisation: 11/12/2009, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 4, 2025 0

Human medicines European public assessment report (EPAR): Rivastigmine Hexal, ri...

Human medicines European public assessment report (EPAR): Rivastigmine 1 A Pharma, rivastigmine, Date of authorisation: 11/12/2009, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 4, 2025 0

Human medicines European public assessment report (EPAR): Rivastigmine 1 A Pharm...

Orphan designation: bexmarilimab Treatment of myelodysplastic syndromes, 25/03/2025 Positive

Orphan designation: bexmarilimab Treatment of myelodysp...

Apr 4, 2025 0

Orphan designation: bexmarilimab Treatment of myelodysplastic syndromes, 25/03/2...

Human medicines European public assessment report (EPAR): Sitagliptin / Metformin hydrochloride Mylan, sitagliptin hydrochloride monohydrate,metformin hydrochloride, Date of authorisation: 16/02/2022, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 4, 2025 0

Human medicines European public assessment report (EPAR): Sitagliptin / Metformi...

Orphan designation: ixodes ricinus contact phase inhibitor Treatment of non-traumatic spontaneous intracerebral haemorrhage, 25/03/2025 Positive

Orphan designation: ixodes ricinus contact phase inhibi...

Apr 4, 2025 0

Orphan designation: ixodes ricinus contact phase inhibitor Treatment of non-trau...

Human medicines European public assessment report (EPAR): Rxulti, brexpiprazole, Date of authorisation: 26/07/2018, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 4, 2025 0

Human medicines European public assessment report (EPAR): Rxulti, brexpiprazole,...

Orphan designation: Felzartamab Treatment of in solid organ transplantation, 13/12/2024 Positive

Orphan designation: Felzartamab Treatment of in solid o...

Apr 4, 2025 0

Orphan designation: Felzartamab Treatment of in solid organ transplantation, 13/...

Orphan designation: deucrictibant monohydrate Treatment of bradykinin-mediated angioedema, 25/03/2025 Positive

Orphan designation: deucrictibant monohydrate Treatment...

Apr 4, 2025 0

Orphan designation: deucrictibant monohydrate Treatment of bradykinin-mediated a...

Orphan designation: Autologous T lymphocyte-enriched population of cells transduced with a lentiviral vector encoding a chimeric antigen receptor targeting human B cell maturation antigen with 4-1BB and CD3-zeta intracellular signalling domains Treatment of multiple myeloma, 04/06/2020 Withdrawn

Orphan designation: Autologous T lymphocyte-enriched po...

Apr 4, 2025 0

Orphan designation: Autologous T lymphocyte-enriched population of cells transdu...

Human medicines European public assessment report (EPAR): Vildagliptin / Metformin hydrochloride Accord, vildagliptin / metformin hydrochloride, Date of authorisation: 24/03/2022, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 4, 2025 0

Human medicines European public assessment report (EPAR): Vildagliptin / Metform...

Human medicines European public assessment report (EPAR): Reblozyl, luspatercept, Date of authorisation: 25/06/2020, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 4, 2025 0

Human medicines European public assessment report (EPAR): Reblozyl, luspatercept...

European Medicines Agency guidance for applicants seeki...

Apr 4, 2025 0

European Medicines Agency guidance for applicants seeking scientific advice and ...

Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 3, 2025 0

Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, ...

Human medicines European public assessment report (EPAR): Lutathera, lutetium (177Lu) oxodotreotide, Date of authorisation: 26/09/2017, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 3, 2025 0

Human medicines European public assessment report (EPAR): Lutathera, lutetium (1...

Human medicines European public assessment report (EPAR): Ronapreve, casirivimab,imdevimab, Date of authorisation: 12/11/2021, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 3, 2025 0

Human medicines European public assessment report (EPAR): Ronapreve, casirivimab...

Human medicines European public assessment report (EPAR): Perjeta, pertuzumab, Date of authorisation: 04/03/2013, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 3, 2025 0

Human medicines European public assessment report (EPAR): Perjeta, pertuzumab, D...

Human medicines European public assessment report (EPAR): RoActemra, tocilizumab, Date of authorisation: 16/01/2009, Revision: 47, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 3, 2025 0

Human medicines European public assessment report (EPAR): RoActemra, tocilizumab...

Human medicines European public assessment report (EPAR): Jinarc, tolvaptan, Date of authorisation: 27/05/2015, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 3, 2025 0

Human medicines European public assessment report (EPAR): Jinarc, tolvaptan, Dat...

Human medicines European public assessment report (EPAR): MabThera, rituximab, Date of authorisation: 02/06/1998, Revision: 63, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 3, 2025 0

Human medicines European public assessment report (EPAR): MabThera, rituximab, D...

Human medicines European public assessment report (EPAR): Seffalair Spiromax, salmeterol,fluticasone propionate, Date of authorisation: 26/03/2021, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 3, 2025 0

Human medicines European public assessment report (EPAR): Seffalair Spiromax, sa...

8
9
10
11
12

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.